Prospects of POLD1 in Human Cancers: A Review

Gola, Michał; Stefaniak, Przemysław; Godlewski, Janusz; Jereczek‐Fossa, Barbara Alicja; Starzyńska, Anna

doi:10.3390/cancers15061905

Cited by 2 publications

(2 citation statements)

References 108 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…FEN1 has been targeted in the development of small‐molecule inhibitors for the treatment of pancreatic cancer 25 . PLOD1 has been targeted in the development of anti‐PLOD1 antibodies for the treatment of lung cancer 26 . PCNA has been targeted in developing small‐molecule inhibitors for treating colorectal and pancreatic cancer 27 .…”

Section: Resultsmentioning

confidence: 99%

“…25 PLOD1 has been targeted in the development of anti-PLOD1 antibodies for the treatment of lung cancer. 26 PCNA has been targeted in developing small-molecule inhibitors for treating colorectal and pancreatic cancer. 27 RAD51 has been targeted in the development of RAD51 inhibitors for the treatment of breast and ovarian cancer.…”

Section: The Distinct Expression Of the Ddr Gene In Dlbcl Is Linked W...mentioning

confidence: 99%

See 1 more Smart Citation

Expression of “DNA damage response” pathway genes in diffuse large B‐cell lymphoma: The potential for exploiting synthetic lethality

Mansoor,

Kamran,

Rizwan

et al. 2023

Hematological Oncology

View full text Add to dashboard Cite

Diffuse large B‐cell lymphoma (DLBCL) and follicular lymphoma (FL) are two of the most prevalent non‐Hodgkin's lymphoma subtypes. Despite advances, treatment resistance and patient relapse remain challenging issues. Our study aimed to scrutinize gene expression distinctions between DLBCL and FL, employing a cohort of 53 DLBCL and 104 FL samples that underwent rigorous screening for genetic anomalies. The NanoString nCounter assay evaluated 730 cancer‐associated genes, focusing on densely tumorous areas in diagnostic samples. Employing the Lymph2Cx method, we determined the cell‐of‐origin (COO) for DLBCL cases. Our meticulous analysis, facilitated by Qlucore Omics Explorer software, unveiled a substantial 37% of genes with significantly differential expression patterns between DLBCL and FL, pointing to nuanced mechanistic disparities. Investigating the impact of FL disease stage and DLBCL COO on gene expression yielded minimal differences, prompting us to direct our attention to consistently divergent genes in DLBCL. Intriguingly, our Gene Set Enrichment Analysis spotlighted 21% of these divergent genes, converging on the DNA damage response (DDR) pathway, vital for cell survival and cancer evolution. Strong positive correlations among most DDR genes were noted, with key genes like BRCA1, FANCA, FEN1, PLOD1, PCNA, and RAD51 distinctly upregulated in DLBCL compared to FL and normal tissue controls. These findings were subsequently validated using RNA seq data on normal controls and DLBCL samples from public databases like The Cancer Genome Atlas (TCGA) and the Genotype‐Tissue Expression (GTEx) databases, enhancing the robustness of our results. Considering the established significance of these DDR genes in solid cancer therapies, our study underscores their potential applicability in DLBCL treatment strategies. In conclusion, our investigation highlights marked gene expression differences between DLBCL and FL, with particular emphasis on the essential DDR pathway. The identification of these DDR genes as potential therapeutic targets encourages further exploration of synthetic lethality‐based approaches for managing DLBCL.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: The Distinct Expression Of the Ddr Gene In Dlbcl Is Linked W...mentioning

confidence: 99%

Expression of “DNA damage response” pathway genes in diffuse large B‐cell lymphoma: The potential for exploiting synthetic lethality

Mansoor,

Kamran,

Rizwan

et al. 2023

Hematological Oncology

View full text Add to dashboard Cite

show abstract

Modeling the Dynamics of Negative Mutations for a Mouse Population and the Inverse Problem of Determining Phenotypic Differences in the First Generation

et al. 2023

View full text Add to dashboard Cite

This paper considers a model for the accumulation of mutations in a population of mice with a weakened function of polymerases responsible for correcting DNA copying errors during cell division. The model uses the results of the experiment published by Japanese scientists, which contain data on the accumulation of phenotypic differences in three isolated groups of laboratory mice. We have developed a model for the accumulation of negative mutations. Since the accumulation of phenotypic differences in each of the three groups of mice occurred in its own way, we assumed that these differences were associated with genotypic differences in the zeroth generation and set the inverse problem of determining the initial distribution of these differences. Additional information for solving the inverse problem was a set of experimental data on the number of mutant lines and the number of individuals in each group of mice. The results obtained confirmed our assumption.

show abstract

Prospects of POLD1 in Human Cancers: A Review

Cited by 2 publications

References 108 publications

Expression of “DNA damage response” pathway genes in diffuse large B‐cell lymphoma: The potential for exploiting synthetic lethality

Expression of “DNA damage response” pathway genes in diffuse large B‐cell lymphoma: The potential for exploiting synthetic lethality

Modeling the Dynamics of Negative Mutations for a Mouse Population and the Inverse Problem of Determining Phenotypic Differences in the First Generation

Contact Info

Product

Resources

About